Marketed as Victoza for type 2 diabetes (approved 2010) and Saxenda for chronic weight management (approved 2014), liraglutide paved the way for the current generation of GLP-1 weight loss medications, including its successor semaglutide
A., Sherr, A., Shirin, S., Solodkina, G., Morales-Tapia, E., Wolf, B., Lifshitz, Y
World Anti-Doping Agency
In: StatPearls [Internet]
Potential Benefits: Supports fat loss by targeting NNMT enzyme activity Helps preserve muscle mass during weight loss Boosts energy and mitochondrial function Best For:Those aiming to optimise body composition, metabolic health, and maintain energy during dieting or cutting phases
Immediately dispose of the used syringe in an approved sharps container